CD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2016 |
| Outros Autores: | , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| DOI: | 10.1097/QAI.0000000000000845 |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/32186 |
Resumo: | Faculdade de Medicina da Universidade de São Paulo. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil. |
| id |
CRUZ_ef9bd930be00975209b2dcc8e9eaf962 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/32186 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Avelino-Silva, VivianMiyaj, Karina TakesakiMathias, AugustoCosta, Dayane AlvesDias, Juliana Zanatta de CarvalhoLima, Sheila BarbosaSimoes, MarisolFreire, Marcos S.Caiaffa-Filho, Helio H.Hong, Marisa A.Lopes, Marta H.Sartori, Ana M.Kallas, Esper Georges2019-03-20T19:34:21Z2019-03-20T19:34:21Z2016AVELINO-SILVA, Vivian Iida et al. CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients. Journal Of Acquired Immune Deficiency Syndromes, Hagerstown, v. 71, n. 2, p.189-195, 2016.1944-7884https://www.arca.fiocruz.br/handle/icict/3218610.1097/QAI.0000000000000845engCD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patientsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFaculdade de Medicina da Universidade de São Paulo. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil.Faculdade de Medicina da Universidade de São Paulo. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil.Faculdade de Medicina da Universidade de São Paulo. Divisão de Clínica de Imunologia e Alergia. São Paulo, SP, Brasil.Faculdade de Medicina da Universidade de São Paulo. Divisão de Clínica de Imunologia e Alergia. São Paulo, SP, Brasil.Faculdade de Medicina da Universidade de São Paulo. Divisão de Clínica de Imunologia e Alergia. São Paulo, SP, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brasil.Instituto Adolfo Lutz. São Paulo, SP, Brasil.Instituto Adolfo Lutz. São Paulo, SP, Brasil / Faculdade de Medicina da Universidade de São Paulo. Divisão de Clínica de Imunologia e Alergia. São Paulo, SP, Brasil.Faculdade de Medicina da Universidade de São Paulo. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil.Faculdade de Medicina da Universidade de São Paulo. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil.Faculdade de Medicina da Universidade de São Paulo. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil / Faculdade de Medicina da Universidade de São Paulo. Divisão de Clínica de Imunologia e Alergia. São Paulo, SP, Brasil.BACKGROUND: Yellow fever vaccine (YFV) induces weaker immune responses in HIV-infected individuals. However, little is known about YFV responses among antiretroviral-treated patients and potential immunological predictors of YFV response in this population. METHODS: We enrolled 34 antiretroviral therapy (ART)-treated HIV-infected and 58 HIV-uninfected adults who received a single YFV dose to evaluate antibody levels and predictors of immunity, focusing on CD4(+) T-cell count, CD4(+)/CD8(+) ratio, and Human Pegivirus (GBV-C) viremia. Participants with other immunosuppressive conditions were excluded. RESULTS: Median time since YFV was nonsignificantly shorter in HIV-infected participants than in HIV-uninfected participants (42 and 69 months, respectively, P = 0.16). Mean neutralizing antibody (NAb) titers was lower in HIV-infected participants than HIV-uninfected participants (3.3 vs. 3.6 log10mIU/mL, P = 0.044), a difference that remained significant after adjustment for age, sex, and time since vaccination (P = 0.024). In HIV-infected participants, lower NAb titers were associated with longer time since YFV (rho: -0.38, P = 0.027) and lower CD4(+)/CD8(+) ratio (rho: 0.42, P = 0.014), but not CD4(+) T-cell count (P = 0.52). None of these factors were associated with NAb titers in HIV-uninfected participant. GBV-C viremia was not associated with difference in NAb titers overall or among HIV-infected participants. CONCLUSIONS: ART-treated HIV-infected individuals seem to have impaired and/or less durable responses to YFV than HIV-uninfected individuals, which were associated with lower CD4(+)/CD8(+) ratio, but not with CD4(+) T-cell count. These results supports the notion that low CD4(+)/CD8(+) ratio, a marker linked to persistent immune activation, is a better indicator of functional immune disturbance than CD4(+) T-cell count in patients with successful ART.Yellow fever vaccineYellow fever neutralizing antibodiesHIVCD4+/CD8+ ratioImmune activationinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1748https://www.arca.fiocruz.br/bitstream/icict/32186/1/license.txt8a4605be74aa9ea9d79846c1fba20a33MD51ORIGINALapplication-pdf.pdfapplication-pdf.pdfapplication/pdf401636https://www.arca.fiocruz.br/bitstream/icict/32186/2/application-pdf.pdf48e9c30e935c58c14f01340738377b59MD52TEXTapplication-pdf.pdf.txtapplication-pdf.pdf.txtExtracted texttext/plain40417https://www.arca.fiocruz.br/bitstream/icict/32186/3/application-pdf.pdf.txt0b37044bf9542bdd4e273ac83919229eMD53icict/321862020-07-10 14:32:27.563oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352020-07-10T17:32:27Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.en.fl_str_mv |
CD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients |
| title |
CD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients |
| spellingShingle |
CD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients Avelino-Silva, Vivian Yellow fever vaccine Yellow fever neutralizing antibodies HIV CD4+/CD8+ ratio Immune activation |
| title_short |
CD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients |
| title_full |
CD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients |
| title_fullStr |
CD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients |
| title_full_unstemmed |
CD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients |
| title_sort |
CD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients |
| author |
Avelino-Silva, Vivian |
| author_facet |
Avelino-Silva, Vivian Miyaj, Karina Takesaki Mathias, Augusto Costa, Dayane Alves Dias, Juliana Zanatta de Carvalho Lima, Sheila Barbosa Simoes, Marisol Freire, Marcos S. Caiaffa-Filho, Helio H. Hong, Marisa A. Lopes, Marta H. Sartori, Ana M. Kallas, Esper Georges |
| author_role |
author |
| author2 |
Miyaj, Karina Takesaki Mathias, Augusto Costa, Dayane Alves Dias, Juliana Zanatta de Carvalho Lima, Sheila Barbosa Simoes, Marisol Freire, Marcos S. Caiaffa-Filho, Helio H. Hong, Marisa A. Lopes, Marta H. Sartori, Ana M. Kallas, Esper Georges |
| author2_role |
author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Avelino-Silva, Vivian Miyaj, Karina Takesaki Mathias, Augusto Costa, Dayane Alves Dias, Juliana Zanatta de Carvalho Lima, Sheila Barbosa Simoes, Marisol Freire, Marcos S. Caiaffa-Filho, Helio H. Hong, Marisa A. Lopes, Marta H. Sartori, Ana M. Kallas, Esper Georges |
| dc.subject.en.en.fl_str_mv |
Yellow fever vaccine Yellow fever neutralizing antibodies HIV CD4+/CD8+ ratio Immune activation |
| topic |
Yellow fever vaccine Yellow fever neutralizing antibodies HIV CD4+/CD8+ ratio Immune activation |
| description |
Faculdade de Medicina da Universidade de São Paulo. Departamento de Doenças Infecciosas e Parasitárias. São Paulo, SP, Brasil. |
| publishDate |
2016 |
| dc.date.issued.fl_str_mv |
2016 |
| dc.date.accessioned.fl_str_mv |
2019-03-20T19:34:21Z |
| dc.date.available.fl_str_mv |
2019-03-20T19:34:21Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
AVELINO-SILVA, Vivian Iida et al. CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients. Journal Of Acquired Immune Deficiency Syndromes, Hagerstown, v. 71, n. 2, p.189-195, 2016. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/32186 |
| dc.identifier.issn.pt_BR.fl_str_mv |
1944-7884 |
| dc.identifier.doi.none.fl_str_mv |
10.1097/QAI.0000000000000845 |
| identifier_str_mv |
AVELINO-SILVA, Vivian Iida et al. CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients. Journal Of Acquired Immune Deficiency Syndromes, Hagerstown, v. 71, n. 2, p.189-195, 2016. 1944-7884 10.1097/QAI.0000000000000845 |
| url |
https://www.arca.fiocruz.br/handle/icict/32186 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/32186/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/32186/2/application-pdf.pdf https://www.arca.fiocruz.br/bitstream/icict/32186/3/application-pdf.pdf.txt |
| bitstream.checksum.fl_str_mv |
8a4605be74aa9ea9d79846c1fba20a33 48e9c30e935c58c14f01340738377b59 0b37044bf9542bdd4e273ac83919229e |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1822792118664429568 |